Myriad GeneticsSTU:MYD -1.68%53 Current Ratio is 2.40 as of Mar. 2026, which is 2% above its 10-year median of 2.36. GuruFocus rates STU:MYD with a GF Score™ of 53/100 and a GF Value™ of €13.15 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Myriad Genetics ranks better than 56.07% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Myriad Genetics's current ratio for the quarter that ended in Mar. 2026 was 2.40.
Myriad Genetics has a current ratio of 2.40. It generally indicates good short-term financial strength.
The historical rank and industry rank for Myriad Genetics's Current Ratio or its related term are showing as below:
STU:MYD'
s Current Ratio Range Over the Past 10 Years
Min: 1.17 Med: 2.36 Max: 4.35
Current: 2.4
During the past 13 years, Myriad Genetics's highest Current Ratio was 4.35. The lowest was 1.17. And the median was 2.36.
STU:MYD's Current Ratio is ranked better than 56.07% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.06
vs STU:MYD: 2.40
Myriad Genetics (STU:MYD) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Myriad Genetics Current Ratio Related Terms
Myriad Genetics Current Ratio Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MYD vs FLGT, CSTL, BDSX: Current Ratio Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (STU:MYD) has a Current Ratio of 2.40 as of Mar. 2026. This is near median its historical median of 2.36. Over the past decade, Myriad Genetics' Current Ratio has ranged from 1.17 to 4.35. According to the industry distribution chart, Myriad Genetics ranks #94 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 43.9%.
Is Myriad Genetics' Current Ratio too high?
Myriad Genetics' current Current Ratio of 2.40 is near median its 10-year median of 2.36. Over the past 10 years, this metric has ranged from a low of 1.17 to a high of 4.35. The Medical Diagnostics & Research industry median Current Ratio is 2.06. Myriad Genetics' value of 2.40 is 16.5% above this industry median. Based on the distribution chart, Myriad Genetics ranks #94 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Myriad Genetics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Current Ratio compare to FLGT and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #94 out of 214 companies for Current Ratio. This puts Myriad Genetics in the upper half of its industry. The industry median Current Ratio is 2.06. Myriad Genetics' value of 2.40 is 16.5% above this benchmark. Historically, Myriad Genetics' own Current Ratio has ranged from 1.17 to 4.35 over the past decade. While the company's 10-year median is 2.36 vs. the industry median of 2.06, Myriad Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.06, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Myriad Genetics's current Current Ratio of 2.40 is 16.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current Current Ratio is 2.40, which is near median its own 10-year median of 2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.15, compared to a current price of €4.96 — trading 62.3% below its estimated fair value. The current Current Ratio is 2.40, which is near median its 10-year median of 2.36 and 16.5% above the Medical Diagnostics & Research industry median of 2.06. Myriad Genetics' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Current Ratio is 2.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (STU:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €4.96 is trading 62.3% below its estimated GF Value™ of €13.15.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for STU:MYD:
Current Ratio: 2.40 (near median its 10-year median of 2.36)
GF Value™: €13.15 vs. price of €4.96 (62.3% below fair value)
Industry Position: 16.5% above the Medical Diagnostics & Research median (#94 of 214)
No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
53GF Score
Get the complete analysis for STU:MYD
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MYD has been successfully added to your 
